NCT05306574Phase 3Terminated

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

Study sponsor: Vor Biopharma

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-01-06Actual
Enrollment · participants91Actual
Source updated2026-01-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 350 participants (planned). After: 91 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 2 Jan 2027. After: 6 Jan 2025.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview